SCHEMBL23123552

SCHEMBL23123552

COc1cc(-c2cn(C)c(=O)c3cnccc23)cc(OC)c1CN1CCN(CC2CCN(C(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD9 Q9H8M2 19/20 0.54
BRD7 Q9NPI1 3/20 0.54
TAF1 P21675 2/20 0.54
TGFBR1 P36897 2/20 0.54
ACVR1 Q04771 2/20 0.54
CREBBP Q92793 2/20 0.54
CECR2 Q9BXF3 2/20 0.54
BRPF1 P55201 1/20 0.54
BPTF Q12830 1/20 0.54
TAF1L Q8IZX4 1/20 0.54
BAZ2B Q9UIF8 1/20 0.54
ATAD2B Q9ULI0 1/20 0.54
CYP3A4 P08684 1/20 0.48
CYP2C19 P33261 1/20 0.48
KCNH2 Q12809 1/20 0.48
VHL P40337 1/20 0.43
ELOC Q15369 1/20 0.43
ELOB Q15370 1/20 0.43
CYP2D6 P10635 1/20 0.42
ACVR2B Q13705 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25933364 0.95 BRD9 (0.49) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL22291253 0.93 BRD9 (0.58) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL30297128 0.92 BRD9 (0.56) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23122723 0.91 BRD9 (0.54) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL33532942 0.90 BRD9 (0.54) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23121776 0.88 BRD9 (0.49) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL30297135 0.88 BRD9 (0.52) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL25933271 0.88 BRD9 (0.54) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23123264 0.87 BRD9 (0.52) BRD9BRD7TAF1TGFBR1ACVR1
SCHEMBL23125025 0.87 BRD9 (0.55) BRD9BRD7TAF1TGFBR1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220315578-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-10-06 US disclosed
EP-4041724-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE Novartis AG (CH) 2022-08-17 EP disclosed
CN-114641473-A BRD9 bifunctional degradation agent and use method thereof 诺华股份有限公司 2022-06-17 CN disclosed
WO-2021055295-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-03-25 WO disclosed
WO-2021055295-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315578-A1 BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE BRD9, BRD2, BRD1 BRD9 1/4885BRD7 5/4885TAF1 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.